New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
11:53 EDTVASC, BSXVascular Solutions: Injunction against Boston Scientific's Guidezilla vacated
Vascular Solutions (VASC) announced that a three judge panel of the U.S. Court of Appeals for the Federal Circuit vacated the preliminary injunction that was previously issued by the District Court for the District of Minnesota effective January 13 against Boston Scientific's (BMY) Guidezilla guide extension catheter. In its one paragraph opinion vacating the injunction, the court noted that a preliminary injunction is a "drastic and extraordinary remedy that is not to be routinely granted" and "at this stage of the case the record is too incomplete . . . to warrant the grant of a preliminary injunction." The court's ruling on the preliminary injunction does not affect the underlying patent litigation, which is currently scheduled to be ready for trial on or after March 2015 in the District Court for the District of Minnesota.
News For VASC;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 22, 2014
09:21 EDTBSXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
08:43 EDTBSXBoston Scientific hasn't changed strategy in selling Synergy in Europe
Subscribe for More Information
08:25 EDTBSXBoston Scientific sees foreign exchange to be $55M headwind in FY14
Subscribe for More Information
08:16 EDTBSXBoston Scientific 'well ahead' of delivering EPS, revenue expectations
Subscribe for More Information
07:07 EDTBSXBoston Scientific raises FY14 adjusted EPS to 81c-83c from 79c-83c
Subscribe for More Information
07:06 EDTBSXBoston Scientific sees Q4 adjusted EPS 20c-22c, consensus 21c
Subscribe for More Information
07:05 EDTBSXBoston Scientific reports Q3 adjusted EPS 20c, consensus 20c
Subscribe for More Information
October 21, 2014
16:21 EDTVASCVascular Solutions sees Q4 EPS 16c-18c, consensus 20c
Subscribe for More Information
16:21 EDTVASCVascular Solutions raises 2014 revenue outlook to $125M-$126M
Previous outlook $123M-$125M. Consensus $123.75M. Due to the non-cash tax adjustment incurred in Q3 and increased legal expenses, Vascular Solutions is revising its GAAP earnings guidance for 2014 to a range of 65c-67c. Consensus 76c.
16:19 EDTVASCVascular Solutions reports Q3 EPS with item 15c, consensus 20c
Subscribe for More Information
15:35 EDTBSXNotable companies reporting before tomorrow's open
Subscribe for More Information
09:03 EDTBSXBoston Scientific receives FDA and CE Mark approvals for CoverEdge leads
Subscribe for More Information
October 20, 2014
08:16 EDTBSXBoston Scientific initiates PLATINUM Diversity trial
Subscribe for More Information
07:20 EDTBSXInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:11 EDTBSXAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 16, 2014
16:32 EDTBSXBoston Scientific announces pacemaker CE mark with options for MRI
Boston Scientific has received CE Mark approval for the ACCOLADE pacemaker family. When implanted with the company's INGEVITY leads, ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems. In addition, the Boston Scientific ImageReady technology offers the most flexible MRI options, allowing higher energy scan sequences, and featuring a programmable MRI timer designed to improve patient workflow. In addition to the CE mark approval and launch of the ACCOLADE pacemaker family, Boston Scientific received CE Mark approval for the VISIONIST and VALITUDE CRT-Ps with quadripolar pacing technology. When paired with the ACUITY X4 pacing leads, these systems offer many options to reach and pace the target location in the left ventricle, potentially improving the patient response to CRT therapy.
15:10 EDTBSXAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
October 8, 2014
20:03 EDTBSXBoston Scientific confirms FDA panel votes for WATCHMAN device
After reviewing updated data and analysis for the Boston Scientific Corporation WATCHMAN Left Atrial Appendage Closure Device, the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the Device. By a vote of 6 to 5, with 1 abstention, the panel concluded that the benefits of the WATCHMAN Device outweigh the potential risks. The panel voted that there is reasonable assurance that the device is safe, with a 12 yes to 0 no vote. On the question of reasonable assurance of effectiveness, the panel vote was unfavorable with a 6 yes to 7 no vote. The panel provided substantial input and guidance related to the proposed Indications for use and target patient population. There was widespread agreement among the panel members that the device provides a much needed alternative to long-term anticoagulation for some patients. While not bound by this vote, the FDA takes Advisory Panel comments and recommendations into account when reviewing the WATCHMAN Device application. The company is committed to working with the FDA to address the panel's comments.
18:42 EDTBSXBoston Scientific Watchman Device receives votes from FDA panel, Dow Jones says
The FDA Panel voted 6 to 5 that benefits of Boston Scientific's Watchman device outweigh the risks, Dow Jones reports. The panel voted 12 to 0 that the Watchman device is safe, and the panel voted 7 to 6 that the Watchman device is not effective, Dow Jones added.
07:24 EDTBSXFDA Circulatory Systems Devices Panel to hold a meeting
The Committee discusses, makes recommendations and votes on information related to the Pre-Market Approval Application regarding Boston Scientificís WATCHMAN Left Atrial Appendage (LAA) Closure Technology in a meeting being held in Gaithersburg, Maryland on October 8 at 8 am. Webcast Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use